PMCID: PMC2935185 ) Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George JN, Kelton JG (2013) Approach to the diagnosis and management of drug-induced immune thrombocytopenia
Routes that Bypass First-Pass Metabolism: Sublingual (e.g., nitroglycerin) Intravenous (IV) Rectal (partial) Transdermal patches Clinical Significance: Important when dosing oral medications to achieve therapeutic effect
Long-Term Safety Data Still Limited The longest published Retatrutide data extends to 68 weeks from the TRIUMPH-4 trial
Long-Term Considerations and Sustainability Weight loss medications work best as part of a comprehensive approach to obesity management
Dosing protocols differ substantially between the two medications, explains OrderlyMeds, which impacts both efficacy timelines and individual tolerance
| | | | | | | GLP-1 Receptor Agonists 2 GLP-1 Receptor Agonists (GLP-1 RAs) (Incretin Mimetic) GLP-1 (Glucagon-like Peptide-1) GLP-1 2 GLP-1 RAs : : Liraglutide (Victoza, Saxenda), Exenatide (Byetta) : Semaglutide (Ozempic, Wegovy), Dulaglutide (Trulicity), Exenatide Extended-Release (Bydureon BCise) : Semaglutide (Rybelsus) GLP-1 RAs : GLP-1 Receptor Agonists GLP-1 : : : (Glucagon) (Gastric Emptying): : GLP-1 Receptor Agonists : 2 (Type 2 Diabetes Mellitus): ( Metformin) (Weight Management): GLP-1 RAs Liraglutide (Saxenda) Semaglutide (Wegovy) : (Major Adverse Cardiovascular Events - MACE) 2 GLP-1 Receptor Agonists : : (pre-filled pen) (Subcutaneous Injection) Liraglutide: (Daily) Semaglutide, Dulaglutide, Exenatide ER: (Weekly) : Semaglutide (Rybelsus) 30 ( 120
